CD30/TNFRSF8 Antibody (Hu8F2) [Unconjugated]

Jurkat human acute T cell leukemia cell line was stained with Human Anti-Human CD30/TNFRSF8 (Brentuximab Biosimilar) F(ab')2 Monoclonal Antibody (Catalog # MAB11129-FAB2, filled histogram) or no antibody (open histogram) followed by APC-conjugated Anti-Human IgG Secondary Antibody (F0135). View our protocol for Staining Membrane-associated Proteins.

Biosimilar antibody development at Bio-Techne includes in silico design and engineering to generate both light chain (lc) and heavy chain (hc) sequences for each antibody. After transfection of the dual expression vector, Bio-Techne’s biosimilar antibodies undergo rigorous application testing to ensure the final biosimilar product is suited for your research needs.

• Reactivity: Hu
• Applications: Flow
• Clone: Hu8F2
• Clonality: Monoclonal
• Host: Human
• Conjugate: Unconjugated

CD30/TNFRSF8 Antibody (Hu8F2) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody For Research Use Only
• Immunogen: Human CD30/TNFRSF8
• Specificity: Detects human CD30/TNFRSF8 in direct ELISAs. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Brentuximab. This product is for research use only.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Human
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD30/TNFRSF8 Antibody (Hu8F2) [Unconjugated]

• CD30 antigen
• CD30
• CD30KI-1
• CD30L receptor
• cytokine receptor CD30
• D1S166EKi-1
• Ki-1 antigen
• Lymphocyte activation antigen CD30
• TNFRSF8
• tumor necrosis factor receptor superfamily member 8
• tumor necrosis factor receptor superfamily, member 8

Background

Brentuximab is a biosimilar directed against the extracellular domain of CD30.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.